RxDoctor Payments Data

Crystal Broussard, MD

Family Medicine · Spring, TXNPI 1588688576

Payments from drug & device makers

$2,357in general payments, 2019–2025

Across 107 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$285
  • Novo Nordisk$276
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$238
  • Johnson & Johnson$230
  • AbbVie$181
  • Supernus Pharmaceuticals, Inc.$101
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,33399%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,357 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$233,588
Medicare patients
599
Services billed
7,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$34,520
MounjaroTirzepatide26$29,500
SynthroidLevothyroxine Sodium28$1,942
Atorvastatin Calcium128$1,614
Np ThyroidThyroid,pork18$1,550
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$1,412
Albuterol Sulfate HfaAlbuterol Sulfate33$1,366
Fluticasone Propionate18$1,351
Estradiol12$1,158
Rosuvastatin Calcium75$1,107
Gabapentin42$1,106
Levothyroxine Sodium124$1,076
Bupropion XlBupropion Hcl46$1,011
Azelastine Hcl13$1,008
Nifedipine ErNifedipine12$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$276$34,52031 claims
Lilly USA, LLCMounjaro$285$29,50026 claims
AbbVieSynthroid$181$1,94228 claims
Acella Pharmaceuticals, LLCNp Thyroid$17$1,55018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →